Use Of Fk506 For The Treatment Of Pulmonary Arterial Hypertension

Abstract

A method of reducing pulmonary arterial hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.


Claims
Download PDF
Document Preview
Document History
  • Publication: May 4, 2017
  • Application: Apr 30, 2012
    AU AU 2012/250974 A
  • Priority: Apr 30, 2012
    US US 2012/0035793 W
  • Priority: May 2, 2011
    US US 201161481317 P

Sign in to the Lens

Feedback